Skip to main
CRVO
CRVO logo

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc. is leveraging a robust financial foundation and promising clinical data to enhance its position in the biotechnology sector, particularly in the treatment of age-related neurologic disorders. The company reported a significant cash position of $38.9 million as of December 31, 2024, providing an operational runway into mid-2026, while research and development expenses increased to $18.8 million, reflecting ongoing investment in its product candidate, Neflamapimod. The positive outcomes from the Phase 2b extension trial, including improved drug exposure and significant clinical benefits, underscore the potential of Neflamapimod, further supporting a positive sentiment toward the company's future prospects.

Bears say

CervoMed Inc. faces significant challenges following disappointing results from the initial phase of the RewinD-LB trial, where the investigational drug demonstrated lower than anticipated plasma drug concentrations, raising concerns about its effectiveness. Compounding these issues, the biotechnology company operates in a competitive landscape with existing and emerging therapies that may hinder its market penetration and pricing capabilities. Additionally, CervoMed's status as a clinical-stage company with no revenue-generating products, coupled with ongoing financial losses and the potential for delays in clinical development and regulatory approvals, further accentuates the financial risks associated with its stock.

CervoMed Inc (CRVO) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 1 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.